Australia · Delayed Price · Currency is AUD Tryptamine Therapeutics Company Description
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States.
The company’s lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness.
It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome.
The company was founded in 2019 and is based in Camberwell, Australia.
| Country | Australia |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Jason Carroll |
Contact Details
Address: 697 Burke Road Camberwell, Victoria 3124 Australia | |
| Phone | 61 3 9092 0475 |
| Website | tryptherapeutics.com |
Stock Details
| Ticker Symbol | TYP |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. James P. Gilligan MSIB, Ph.D. | President and Chief Scientific Officer |
| Christopher Leo Ntoumenopoulos | Executive Director |
| Dr. William James Garner M.D. | Founder and MD |
| Hamish George B.Com., C.A. | Chief Financial Officer and Company Secretary |
| Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D. | Chief Medical Officer |